|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 808 KRW | +0.50% |
|
-12.08% | +29.49% |
TS Nexgen Co., Ltd. (KOSDAQ:A043220) agreed to acquire remaining 48.74% stake in TS CellMedi Co., Ltd. for KRW 2,636.7 million on August 19, 2022. The merger contract date is August 22, 2022. The Board resolution date is August 19, 2022.
The merger ratio is fixed and it is 1: 24.10947003. The number of newly merged stocks is 2.292738 million. TS CellMedi has reported total assets of KRW 4,025.85 million on December 31, 2021.
The transaction is expected to complete on October 24, 2022.
| 1st Jan change | Capi. | |
|---|---|---|
| +29.49% | 67.78M | |
| +20.48% | 90.86B | |
| +42.83% | 24.55B | |
| +37.12% | 16.28B | |
| +22.71% | 10.21B | |
| +4.91% | 8.52B | |
| +35.20% | 8.09B | |
| +1.95% | 7.54B | |
| +161.16% | 6.83B | |
| +51.72% | 5.29B |
TS NEXGEN CO., LTD. 
